Business Description
Klaria Pharma Holding AB
ISIN : SE0007280326
Total Employee Number:
4Compare
Compare
Traded in other countries / regions
KLAR.Sweden6FN.Germany IPO Date
2020-11-02Description
Klaria Pharma Holding AB is a Swedish pharmaceutical company that develops rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Its patented drug delivery platform consists of an alginate-based polymer film that enables the absorption of a product's active substance through the oral mucosa.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | -0.69 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -3.56 | |||||
Beneish M-Score | 77.28 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -21.2 | |||||
3-Year EBITDA Growth Rate | 53.8 | |||||
3-Year EPS without NRI Growth Rate | 41.9 | |||||
3-Year FCF Growth Rate | 39.5 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 14.61 | |||||
9-Day RSI | 31.55 | |||||
14-Day RSI | 38.83 | |||||
3-1 Month Momentum % | 2.25 | |||||
6-1 Month Momentum % | 7.39 | |||||
12-1 Month Momentum % | 117.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.06 | |||||
Quick Ratio | 0.06 | |||||
Cash Ratio | 0.01 | |||||
Days Sales Outstanding | 5256.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -45.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -24767.13 | |||||
Net Margin % | -32132.87 | |||||
EBITDA Margin % | -16386.71 | |||||
FCF Margin % | -25223.08 | |||||
OCF Margin % | -25223.08 | |||||
ROA % | -102.86 | |||||
ROIC % | -38.98 | |||||
3-Year ROIIC % | -109.91 | |||||
ROC (Joel Greenblatt) % | -4369.23 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 1.41 | |||||
PS Ratio | 16.25 | |||||
EV-to-EBIT | -6.05 | |||||
EV-to-Forward-EBIT | 1 | |||||
EV-to-EBITDA | -9.15 | |||||
EV-to-Forward-EBITDA | 1 | |||||
EV-to-Revenue | 1498.69 | |||||
EV-to-Forward-Revenue | 0.44 | |||||
EV-to-FCF | -5.95 | |||||
Price-to-GF-Value | 1.99 | |||||
Earnings Yield (Greenblatt) % | -16.53 | |||||
FCF Yield % | -18.78 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Klaria Pharma Holding AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.013 | ||
| EPS (TTM) (€) | -0.024 | ||
| Beta | 2.0813 | ||
| 3-Year Sharpe Ratio | 0.7 | ||
| 3-Year Sortino Ratio | 1.84 | ||
| Volatility % | 106.22 | ||
| 14-Day RSI | 38.83 | ||
| 14-Day ATR (€) | 0.003317 | ||
| 20-Day SMA (€) | 0.068355 | ||
| 12-1 Month Momentum % | 117.52 | ||
| 52-Week Range (€) | 0.0308 - 0.1185 | ||
| Shares Outstanding (Mil) | 245.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Klaria Pharma Holding AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Klaria Pharma Holding AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-26 | In 149 days | ||
| Second quarter earnings results for 2026 | 2026-08-27 | In 58 days | ||
| Annual report for 2025 | 2026-05-29 | 0.07 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-29 | 0.07 (+0.00%) | ||
| General meeting for 2025 | 2026-05-26 10:00 | 0.07 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-20 | 0.07 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-26 | 0.04 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-28 | 0.04 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-21 | 0.08 (+0.00%) | ||
| General meeting for 2024 | 2025-05-15 13:00 | 0.08 (+0.00%) |
Show
Entries
Klaria Pharma Holding AB Frequently Asked Questions
What is Klaria Pharma Holding AB(FRA:6FN)'s stock price today?
The current price of FRA:6FN is €0.06. The 52 week high of FRA:6FN is €0.12 and 52 week low is €0.03.
When is next earnings date of Klaria Pharma Holding AB(FRA:6FN)?
The next earnings date of Klaria Pharma Holding AB(FRA:6FN) is 2026-08-27.
Does Klaria Pharma Holding AB(FRA:6FN) pay dividends? If so, how much?
Klaria Pharma Holding AB(FRA:6FN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Klaria Pharma Holding AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers